TREATMENT OF SMALL CELL LUNG CANCER WITH A PARP INHIBITOR

Described are methods of treatment of a small cell lung cancer subject expressing Schlafen-11 (SLFN 11 ) with a Poly (ADP-ribose) polymerases (PARP) inhibitor or a pharmaceutically acceptable salt thereof. Specifically, the method comprising detecting SLFN 11 in a tumor cell sample from the subject,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yuqiao SHEN, Yuanbin RU, Leonard E. POST, Evelyn WANG, Karen YU, Ying FENG
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Described are methods of treatment of a small cell lung cancer subject expressing Schlafen-11 (SLFN 11 ) with a Poly (ADP-ribose) polymerases (PARP) inhibitor or a pharmaceutically acceptable salt thereof. Specifically, the method comprising detecting SLFN 11 in a tumor cell sample from the subject, and administering effective amount of a PARP inhibitor, such as talazoparib or the tosylate salt of talazoparib, to the subject. :. Se describen métodos para el tratamiento de un sujeto con cáncer de pulmón de células pequeñas que expresa Schlafen-11 (SLFN 11) con un inhibidor de poli(ADP-ribosa) polimerasas (PARP) o una sal farmacéuticamente aceptable del mismo. Específicamente, el método comprende la detección de SLFN 11 en una muestra de células tumorales del sujeto, y la administración al sujeto de una cantidad eficaz de un inhibidor de PARP, tal como talazoparib o la sal de tosilato de talazoparib.